Use of SERP-1 as an antiplatelet agent

Details Use of SERP-1 as an antiplatelet agent Use of SERP-1 as an antiplatelet agent

2007-10-23

2007-10-23

Carlson, Karen Cochrane (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C435S183000

Reexamination Certificate

active

11256257

ABSTRACT:
Compositions and methods for antiplatelet/anti-thrombotic therapy in a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1 admixed with a pharmaceutically acceptable carrier to a subject in need of such therapy. Methods of administering SERP-1 with at least one other antiplatelet agent are also provided. The compositions and methods of the present invention are useful for treating and preventing recurrence of numerous cardiovascular diseases and injuries.

REFERENCES:
patent: 5686409 (1997-11-01), McFadden et al.
patent: 5917014 (1999-06-01), McFadden et al.
patent: 5939525 (1999-08-01), McFadden et al.
Jiang et al., 1997; Characterization and functional analysis of 12 naturally occurring reactive site variants of serpin-1 from Manduca sexta. J. Biol. Chem 272(2): 1082-1987.
Zalia, C. V. et al., “Increased Circulating Monocyte Activation in Patients With Unstable Coronary Syndromes”,Journal of the American College of Cardiology, 38(5): 1340-1347 (2001).
Nash, P. et al., “Inhibitory Specificity of the Anti-Inflammatory Myxoma Virus Serpin, SERP-1”,The Journal of Biological Chemistry, 273(33): 20982-20991 (1998).
Lomas, D. A. et al., “Inhibition of Plasmin, Urokinase, Tissue Plasminogen Activator, and Cisby a Myxoma Virus Serine Proteinase Inhibitor”,The Journal of Biological Chemistry, 268(1): 516-521 (1993).
Lucas, A. et al., “Virus-Encoded Serine Proteinase Inhibitor SERP-1 Inhibits Atherosclerotic Plaque Development After Balloon Angioplasty”,Circulation, 94: 2890-2900 (1996).
Lucas, A. et al., “Transplant Vasculopathy: Viral Anti-Inflammatory Serpin Regulation of Atherogenesis”,J. Heart Lung Transplant., 19: 1029-1038 (2000).
Miller, L. W. et al., “Inhibition of Transplant Vasculopathy in a Rat Aortic Allograft Model After Infusion of Anti-Inflammatory Viral Serpin”,Circulation, 101: 1598-1605 (2000).
Bot, I. et al., “Serine Protease Inhibitor Serp-1 Strongly Impairs Atherosclerotic Lesion Formation and Induces a Stable Plaque Phenotype in ApoE−/−Mice”,Cir. Res., 93: 464-471 (2003).
Brahn, E. et al., “Suppression of Collagen-Induced Arthritis With a Serine Proteinase Inhibitor cloned From a Myxoma Viral Sequence”,American College of Rheumatology Meeting, Nov. 13-17, 1999, Abstract.
Bedard, E. et al., “Viral Proteins: A Novel Approach to Preventing Chronic Rejection”,American Society of Transplant Surgeons(2002), Abstract.
Wang, H. et al., “Serp-1, a viral anti-inflammatory serpin, attenuates acute xenograft rejection in a rat-to-mouse cardiac transplant model”,7thInternational Congress of Xenotransplantation(2003), Abstract.
Dai, E. et al., “Serp-1, a Viral Anti-inflammatory Serpin, Regulates Cellular Serine Proteinase and Serpin Repsonses to Vascular Injury”,The Journal of Biological Chemistry, 278(20): 18563-18572 (2003).
Viswanathan, K. et al., “Serpins—A Link Between The Thrombolytic and Innate Immune Response Pathways”,Scientific Session of the American Heart Association Meeting, Nov. 7-10, 2004, Abstract.
Viswanathan, K. et al., “Serpins—A Link Between The Thrombolytic and Innate Immune Response Pathways”,Canadian Cardivascular Congress, Oct. 23-27, 2004, Abstract.
Viswanathan, K. et al., “The Anti-inflammatory Viral Serpin Serp-1, Inhibits Human Monocyte Cell Activation”,Sixth World Congress on Inflammation Meeting, Aug. 2-6, 2003, Abstract.
Viswanathan, K. et al., “Serp-1, A Viral Anti-Inflammatory and Anti-Atherogenic Protein Sequentially Alters Membrane Fluidity in Activated Human Atherogenic Cells”,Canadian Cardiovascular Congress, Oct. 24-29, 2003, Abstract.
Lucas, A. et al., “Regulation of Vascular Innate Immune Responses by Viral and Mammalian Serpins”,XIII International Vascular Biology Meeting, Jun. 1-5, 2004, Abstract.
Dai, E. et al., “Evaluation of the Effects of Viral Serpin Infusion on Plaque Growth After Aortic Transplant Using PAI-1-/- Mouse Model”,Canadian Cardiovascular Congress, Oct. 24-29, 2003, Abstract.
Dai, E. et al., “Viral Serpin Regulation of Transplant Vasculopathy Development”,Canadian Cardiovascular Congress, Oct. 26-30, 2002, Abstract.

Affiliated with

Also associated with

Rating

Use of SERP-1 as an antiplatelet agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of SERP-1 as an antiplatelet agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of SERP-1 as an antiplatelet agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3888105